If approved, Amgen and Allergan’s biosimilar – called ABP ... last month at a 10% discount to Roche’s US list price, initially only for Rituxan’s oncology indications as it has agreed ...
South Korea's Celltrion has already filed its rituximab biosimilar in Europe in November. Sandoz's biosimilar adds to a long list of biosimilars under review in Europe, including two versions of ...
The EMA CHMP has adopted a positive opinion recommending the launch of its proposed Rituximab biosimilar Ituxredi in European markets, the Hyderabad-based company said in a regulatory filing.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback